NASDAQ:ACADACADIA Pharmaceuticals Stock Price, Forecast & News

ACADIA Pharmaceuticals' stock was trading at $36.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ACAD stock has increased by 49.5% and is now trading at $55.13. View which stocks have been most impacted by Coronavirus.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 1 hold rating and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.09. The biopharmaceutical company had revenue of $90.07 million for the quarter, compared to analyst estimates of $90.76 million. ACADIA Pharmaceuticals had a negative net margin of 64.99% and a negative return on equity of 39.40%. The business's revenue for the quarter was up 43.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.59) earnings per share. View ACADIA Pharmaceuticals' earnings history.

ACADIA Pharmaceuticals updated its FY 2020 After-Hours earnings guidance on Thursday, May, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $420-450 million, compared to the consensus revenue estimate of $449.8 million.

16 equities research analysts have issued 1-year price objectives for ACADIA Pharmaceuticals' stock. Their forecasts range from $31.00 to $72.00. On average, they anticipate ACADIA Pharmaceuticals' stock price to reach $58.56 in the next year. This suggests a possible upside of 6.2% from the stock's current price. View analysts' price targets for ACADIA Pharmaceuticals.

Headlines about ACAD stock have been trending extremely negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ACADIA Pharmaceuticals earned a daily sentiment score of -4.3 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the stock's share price in the next few days. View the latest news about ACADIA Pharmaceuticals.

Some companies that are related to ACADIA Pharmaceuticals include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Royalty Pharma (RPRX), Shiseido (SSDOY), UCB (UCBJF), Alexion Pharmaceuticals (ALXN), Genmab A/S (GMAB), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG) and Sarepta Therapeutics (SRPT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), Sarepta Therapeutics (SRPT), Celgene (CELG), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Synergy Pharmaceuticals (SGYP), Netflix (NFLX), Omeros (OMER) and Citigroup (C).

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

ACADIA Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include MERIAN GLOBAL INVESTORS UK Ltd (0.68%), International Biotechnology Trust PLC (0.20%) and Exane Derivatives (0.00%). Company insiders that own ACADIA Pharmaceuticals stock include Austin D Kim, Bros Advisors Lp Baker, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic and Stephen Davis. View institutional ownership trends for ACADIA Pharmaceuticals.

ACAD stock was sold by a variety of institutional investors in the last quarter, including International Biotechnology Trust PLC, and Exane Derivatives. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Austin D Kim, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic, and Stephen Davis. View insider buying and selling activity for ACADIA Pharmaceuticals.

ACAD stock was acquired by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd. View insider buying and selling activity for ACADIA Pharmaceuticals.

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ACAD stock can currently be purchased for approximately $55.13.

ACADIA Pharmaceuticals has a market capitalization of $8.59 billion and generates $339.08 million in revenue each year. The biopharmaceutical company earns $-235,260,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. ACADIA Pharmaceuticals employs 465 workers across the globe.

The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com.

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]